2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1Medical and Surgical Management of Empyema
Godfrey M, Bramley K, Detterbeck F. Medical and Surgical Management of Empyema. Seminars In Respiratory And Critical Care Medicine 2019, 40: 361-374. PMID: 31525811, DOI: 10.1055/s-0039-1694699.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsVideo-assisted thoracic surgeryChest tube drainageCommon clinical problemIntrapleural fibrinolyticsSurgical decorticationMost patientsTube drainageClinical courseSurgical managementTherapeutic optionsThoracic surgeryPresent cliniciansPleural spaceClinical problemDisease processEarly interventionCulture resultsEarly drainagePhysiologic impactEmpyemaMultidisciplinary collaborationClear benefitCliniciansAntibioticsIntervention
2014
Approaching the Patient with an Anterior Mediastinal Mass: A Guide for Clinicians
Carter BW, Marom EM, Detterbeck FC. Approaching the Patient with an Anterior Mediastinal Mass: A Guide for Clinicians. Journal Of Thoracic Oncology 2014, 9: s102-s109. PMID: 25396306, DOI: 10.1097/jto.0000000000000294.Peer-Reviewed Original Research
2012
Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review
Bach PB, Mirkin JN, Oliver TK, Azzoli CG, Berry DA, Brawley OW, Byers T, Colditz GA, Gould MK, Jett JR, Sabichi AL, Smith-Bindman R, Wood DE, Qaseem A, Detterbeck FC. Benefits and Harms of CT Screening for Lung Cancer: A Systematic Review. JAMA 2012, 307: 2418-2429. PMID: 22610500, PMCID: PMC3709596, DOI: 10.1001/jama.2012.5521.Peer-Reviewed Original ResearchConceptsLow-dose computed tomographyLung cancer mortalityLung cancerLDCT screeningCancer deathCancer mortalityEffect of LDCTSystematic reviewNational Lung Screening TrialEvidence-based clinical guidelinesFrequency of followLung cancer deathsLung cancer screeningRisk of deathPotential harmAdvanced diseaseCause mortalityCohort studyMost patientsSecondary outcomesMajor complicationsPrimary outcomeRandomized studyRandomized trialsCT screening